Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies immune cell receptors in people with lupus

Compares immune cell receptor levels in active and inactive systemic lupus patients.

Plain-language title generated from the registry record
Registry title: Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus

Key facts

Where
Tours, FranceSee the site

Where in France

  • University hospitalTours, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Tours
Trial code
NCT05859191
Record updated
30 April 2026
Original description
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.Read full original descriptionShow less

Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus

This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.

Inclusion: Age ≥ 18 years; Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's; Lupus patient, newly diagnosed or known, untreated or in relapse; Lupus patient considered stable by the treating practitioner; Requiring blood sampling for follow-up.

Exclusion: Main autoimmune disease other than lupus; Patient under legal protection, guardianship or curators; Opposition to data processing.

ClinicalTrials.gov NCT05859191